I2286

Irbesartan

≥98% (HPLC), angiotensin II type 1 (AT1) receptor antagonist, powder

• Synonym(s): 2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, Avapro, BMS-186295, SR-47436
• Empirical Formula (Hill Notation): C₂₅H₂₈N₆O
• CAS Number: 138402-11-6
• Molecular Weight: 428.53
• UNSPSC Code: 12352200
• PubChem Substance ID: 329815365
• NACRES: NA.77
• MDL number: MFCD00864464
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Product Name: Irbesartan, ≥98% (HPLC), powder
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >25 mg/mL
• originator: Bristol-Myers Squibb, Sanofi Aventis
• storage temp.: 2-8°C
• SMILES string: CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5
• InChI: 1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
• InChI key: YOSHYTLCDANDAN-UHFFFAOYSA-N
• Gene Information: human ... AGTR1(185)

Description

General description

Irbesartan comprises bipentyl-tetrazole side chain. It is an imidazole derivative with high bioavailability and is metabolized by the enzyme cytochrome P450 2C9 isoenzyme in liver to be majorly eliminated by oxidation and glucuronidation.[1]

Application

Irbesartan has been used as an angiotensin II receptor type 1 (ATR1) blocker in carotid atheroma tissue.[2][3] It may be used to test its effect on allergic asthma in rat and mice mast cells.[4]

Biochem/physiol Actions

Irbesartan is an angiotensin II type 1 (AT1) receptor antagonist with antihypertensive activity.[1] It also elicits selective peroxisome proliferator-activated receptor γ (PPARγ)-modulating activity and possesses anti-inflammatory properties.[1] Irbesartan shows protective cardiovascular effects[1] and provides protection against chronic glomerulonephritis.[4]

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Bristol-Myers Squibb and Sanofi Aventis. To browse the list of other pharma-developed compounds, Approved Drugs, and Drug Candidates, click here.

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable